This search usually comes from one of two places: someone on Ozempic wondering whether something better is coming, or someone who has seen retatrutide’s numbers and wants to know how it stacks up.
Both deserve a straight answer, and the answer starts with a distinction most articles skip.
Ozempic is not a weight-loss drug
Ozempic® is semaglutide, approved for type 2 diabetes. Wegovy® is the same molecule at weight-management dosing, approved for chronic weight management.
Clinicians do prescribe Ozempic off-label for weight, and insurers frequently decline to cover it when they do — because the label says diabetes. If weight is your goal and you want coverage, Wegovy is usually the conversation to have.
Retatrutide is not approved for anything. It is an Eli Lilly investigational compound, research code LY3437943, currently in phase 3.
So the comparison is not drug A versus drug B. It is a marketed product versus a candidate.
Where they differ mechanically
| Ozempic® (semaglutide) | Retatrutide | |
|---|---|---|
| Receptors | GLP-1 | GLP-1, GIP, glucagon |
| Approved for | Type 2 diabetes | Nothing — investigational |
| Weight loss | 15–17.5% (at Wegovy dosing) | 24.2–28.7% in trials |
| Available | Yes | No |
| Insurance | Covered for diabetes | Not applicable |
Ozempic acts on one receptor. Retatrutide acts on three, and the third — glucagon — increases energy expenditure rather than only reducing appetite.
The internet calls retatrutide a “GLP-3.” There is no such hormone. It is shorthand for a triple agonist, and it is a nickname rather than a classification.
What the numbers mean, and do not mean
Retatrutide’s phase 3 TRIUMPH-4 topline reported roughly 28.7% mean weight loss over 68 weeks at the 12 mg dose. Semaglutide at weight-management dosing sits around 15–17.5%.
That looks decisive. Three cautions:
No head-to-head trial exists. Comparing across studies with different populations, durations, and endpoints is indicative, not conclusive.
Ozempic’s numbers come from diabetes dosing. The like-for-like comparison on weight is Wegovy, not Ozempic.
One has long-term data, the other has none. Semaglutide has years of post-marketing surveillance and cardiovascular outcome data. Retatrutide has trial results and no real-world record.
If you are on Ozempic now
Nothing here is a reason to stop.
If it is working, it is working. If it is not, the productive conversation is with your prescriber about dose, adherence, or switching to tirzepatide — which is available now and sits between semaglutide and retatrutide on both mechanism and efficacy.
Waiting for retatrutide means waiting through phase 3 completion, submission, review, launch, and supply stabilisation. That is 2027 at the earliest, and approval is not guaranteed.
If you are considering buying retatrutide online
Peptide vendors sell it as “research use only.” That phrase is a legal position, not a quality guarantee.
Those vendors are not pharmacies. There is no clinician overseeing dose, titration, or adverse events. Glucagon agonism is the least-mapped of the three mechanisms and the one where oversight matters most. The trial results everyone quotes were produced under monitoring that does not ship with the product.
The verdict
Ozempic if you have type 2 diabetes. That is what it is approved for and what insurance covers.
Wegovy or Zepbound if weight is the goal. Right label, better coverage odds.
Retatrutide — nothing to decide. Revisit if it launches.
If cost is the real obstacle, our cost guides cover every payment route, including several most people never check.
Educational information, not medical advice. Treatment decisions belong with a licensed clinician.